Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric or Gastroesophageal Adenocarcinoma (ROSETTE Trial): an Open-label, Single-center, Randomized Phase 2 Trial
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 84
- 试验地点
- 2
- 主要终点
- Event-Free Survival (EFS) Rate
研究概览
简要总结
ROSETTE trial is an open-label, randomized phase II study designed to investigate treatment strategies for patients with limited metastatic gastric or gastroesophageal adenocarcinoma. Eligible patients are randomized to receive either systemic treatment followed by surgeon-led local treatment, or systemic treatment alone. Systemic treatment combines immunotherapy with chemotherapy, with or without targeted therapy, while the surgeon-led local treatment utilizes a surgery-centric, multi-modality approach involving resection of both primary and metastatic tumors where feasible. For unresected or unresectable metastatic lesions, alternative local therapies are provided. The primary endpoint is the 1-year event-free survival (EFS) rate. Secondary endpoints include objective response rate (ORR), disease control rate (DCR), extended EFS, overall survival (OS), pathologic complete response rate (pCR), major pathologic response rate (MPR), and R0 resection rate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women aged 18-
- •Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (Siewert II or III only) with known PD-L1 expression status.
- •Gastric cancer with proficient mismatch repair (pMMR) or microsatellite stability (MSS) as determined by immunohistochemistry or NCI-recommended microsatellite markers.
- •Primary gastric cancer lesions are resectable, with limited distant metastases meeting the either of the following criteria: (1) condition (a) only; (2) any single condition from (b), with or without (a).
- •(a) Non-regional intra-abdominal lymph node metastasis: Include metastasis to the superior mesenteric artery, middle colic artery, and para-aortic/retroperitoneal nodes (according to AJCC 8th edition standards).
- •(b1) Localized peritoneal metastasis: P0CY1, P1a, or P1b, according to the Japanese Classification of Gastric Carcinoma (15th edition).
- •(b2) Liver metastasis: Up to 5 metastatic lesions. (b3) Lung metastasis: Up to 5 unilateral metastatic lesions. (b4) Ovarian metastasis: Unilateral or bilateral. (b5) Adrenal metastasis: Unilateral or bilateral. (b6) Single-region extra-abdominal lymph node metastasis: Such as cervical, supraclavicular, or mediastinal lymph nodes.
- •(b7) Bone metastasis limited to a single radiation field. (b8) Other limited metastases as determined by the research team.
- •No previous anti-tumor treatments.
- •ECOG score ≤2, no surgical contraindications.
- •Life expectancy ≥ 3 months.
- •Physical condition and organ function suitable for major abdominal surgery.
- •Willingness and ability to comply with the study protocol.
- •Fertile women with a negative urine or serum pregnancy test and agreement to use effective contraception during the study and for 180 days after the last dose. Non-sterilized men must also agree to use effective contraception.
- •Signed informed consent with an understanding that patients can withdraw anytime.
排除标准
- •Inability to tolerate oral chemotherapy.
- •Primary gastric lesion confined to the mucosa or submucosa with isolated ovarian metastasis.
- •Central nervous system metastasis and/or carcinomatous meningitis.
- •Allergy to any components of the study medication.
- •History of previous malignancies or concurrent other malignancies, with the exception of completely resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, and other tumors with no recurrence for at least 5 years.
- •Uncontrolled pleural effusion, pericardial effusion, or ascites.
- •Weight loss ≥20% within two months before enrollment.
- •Upper gastrointestinal obstruction or physiological dysfunction.
- •Previous cytotoxic chemotherapy, radiotherapy, immunotherapy, or curative surgery.
- •Prior PD-1/PD-L1/PD-L2 or other T-cell-targeting therapy.
- •Systemic steroid or immunosuppressant use within 14 days before enrollment.
- •Live vaccine within four weeks prior to enrollment.
- •Uncontrolled systemic disease.
- •Active or past autoimmune diseases that may recur.
- •Severe chronic infections or active infections requiring systemic antibacterial, antifungal, or antiviral treatment.
- •History of lung disease.
- •Pregnancy, lactation, or planning for pregnancy.
- •HBsAg-positive with HBV DNA ≥500 IU/mL.
- •Positive HIV antibody.
- •Conditions that may impact study compliance or participation.
研究组 & 干预措施
Local Treatment Arm (Arm A)
In Phase 1, patients will receive four cycles of PD-1 antibody in combination with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate disease progression status. Patients identified as not experiencing progression will proceed with the study treatments. Subsequently, they will undergo surgeon-led local treatment, which may include standard D2 gastrectomy and metastasectomy when feasible. Non-surgical local treatments may also be administered to address unresected or unresectable metastatic lesions, either concurrently or sequentially with surgery. After surgical intervention, patients will receive up to four additional cycles of XELOX chemotherapy, followed by maintenance therapy consisting of tislelizumab and capecitabine during Phase 2 of the systemic treatment. The total treatment duration may extend up to two years from the date of enrollment.
干预措施: PD-1 Monoclonal Antibody (Drug)
Local Treatment Arm (Arm A)
In Phase 1, patients will receive four cycles of PD-1 antibody in combination with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate disease progression status. Patients identified as not experiencing progression will proceed with the study treatments. Subsequently, they will undergo surgeon-led local treatment, which may include standard D2 gastrectomy and metastasectomy when feasible. Non-surgical local treatments may also be administered to address unresected or unresectable metastatic lesions, either concurrently or sequentially with surgery. After surgical intervention, patients will receive up to four additional cycles of XELOX chemotherapy, followed by maintenance therapy consisting of tislelizumab and capecitabine during Phase 2 of the systemic treatment. The total treatment duration may extend up to two years from the date of enrollment.
干预措施: Local treatment (Surgical) (Procedure)
Local Treatment Arm (Arm A)
In Phase 1, patients will receive four cycles of PD-1 antibody in combination with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate disease progression status. Patients identified as not experiencing progression will proceed with the study treatments. Subsequently, they will undergo surgeon-led local treatment, which may include standard D2 gastrectomy and metastasectomy when feasible. Non-surgical local treatments may also be administered to address unresected or unresectable metastatic lesions, either concurrently or sequentially with surgery. After surgical intervention, patients will receive up to four additional cycles of XELOX chemotherapy, followed by maintenance therapy consisting of tislelizumab and capecitabine during Phase 2 of the systemic treatment. The total treatment duration may extend up to two years from the date of enrollment.
干预措施: XELOX Chemotherapy Regimen (Drug)
Local Treatment Arm (Arm A)
In Phase 1, patients will receive four cycles of PD-1 antibody in combination with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate disease progression status. Patients identified as not experiencing progression will proceed with the study treatments. Subsequently, they will undergo surgeon-led local treatment, which may include standard D2 gastrectomy and metastasectomy when feasible. Non-surgical local treatments may also be administered to address unresected or unresectable metastatic lesions, either concurrently or sequentially with surgery. After surgical intervention, patients will receive up to four additional cycles of XELOX chemotherapy, followed by maintenance therapy consisting of tislelizumab and capecitabine during Phase 2 of the systemic treatment. The total treatment duration may extend up to two years from the date of enrollment.
干预措施: Local Treatment (Non-surgical) (Procedure)
Systemic Treatment Arm (Arm B)
In Phase 1, patients will receive four cycles of PD-1 antibody in conjunction with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate the disease progression status. Patients classified as not experiencing progression-defined as the absence of local progression, advancement of existing distant metastases, or the emergence of new distant metastatic lesions-will continue with the study treatments. In Phase 2, participants will receive an additional up to four cycles of PD-1 antibody and XELOX chemotherapy, followed by maintenance therapy consisting of PD-1 antibody and capecitabine. The total treatment duration could extend up to two years from the date of enrollment.
干预措施: PD-1 Monoclonal Antibody (Drug)
Systemic Treatment Arm (Arm B)
In Phase 1, patients will receive four cycles of PD-1 antibody in conjunction with XELOX chemotherapy. Following this phase, a radiologic assessment will evaluate the disease progression status. Patients classified as not experiencing progression-defined as the absence of local progression, advancement of existing distant metastases, or the emergence of new distant metastatic lesions-will continue with the study treatments. In Phase 2, participants will receive an additional up to four cycles of PD-1 antibody and XELOX chemotherapy, followed by maintenance therapy consisting of PD-1 antibody and capecitabine. The total treatment duration could extend up to two years from the date of enrollment.
干预措施: XELOX Chemotherapy Regimen (Drug)
结局指标
主要结局
Event-Free Survival (EFS) Rate
时间窗: 1 year from the time of randomization
Defined as the time from randomization to the first occurrence of any event, including disease progression (local progression, local recurrence, progression of existing distant metastatic lesions, or the emergence of new distant metastases) or death from any cause.
次要结局
- Objective Response Rate (ORR)(From randomization to the date of completing phase 1 systemic treatment, an average of 12 weeks.)
- Disease Control Rate (DCR)(From randomization to the date of completing phase 1 systemic treatment, an average of 12 weeks.)
- Pathological Complete Response (pCR) Rate(From randomization to the date of surgery, an average of 14 weeks.)
- Major Pathologic Response Rate (MPR)(From randomization to the date of surgery, an average of 14 weeks.)
- R0 Resection Rate(From randomization to the date of surgery, an average of 14 weeks.)
- Overall Survival (OS)(Up to 5 years follow-up)
- Event-Free Survival (EFS)(Up to 5 years follow-up)
研究者
Xuefei.Wang
Chief of Gastrointestinal Surgery Department
Shanghai Zhongshan Hospital